Aurora Cannabis Inc

image-2019-05-02 (4)
Sector: HealthcareCountry: CanadaWKN: A12GS7Equity Ticker Germany: 21P
Sub-sector: Alternative Medicine /CannabisEquity Ticker Canada: ACBISIN: CA05156X1087Shares outstanding: 1,010,000,000


Twitter News Aurora Cannabis Inc


MD&A quarterly as of 31.12.2018

Financial Reports


Condensed Interim Consolidated Financial

Statements as of 31.12.2018

  • Aurora Cannabis
    10355 Jasper Avenue Suite
    500 Edmonton, AB



    Phone: 1-855-279-4652

    Email: [email protected]

    Robert Kelly

    Director of Investor Relations


    Marc Lakmaaker

    VP, Investor Relations and Corporate Development


Terry Booth

Chief Executive OfficerCEO of 6 successful companies
with 25 years experience in highly
regulated industries

Steve Dobler

Successful entrepreneur, member of
many public companies’ board of
directors. Responsible for raising
substantial funds for Aurora

Allan Cleiren

Chief Operating Officer
Experienced operational executive
with nearly three decades leadership
experience at private and public

Jonathan Page

Chief Science Officer
Globally renowned cannabis scientist.
Co-lead of the Canadian team of
scientists who first sequenced the
cannabis genome. Co-Founder of
Anandia Labs

Cam Battley

Chief Corporate Officer
Deep experience in pharma and
cannabis sectors, Board member
Cannabis Canada

Glen Ibbott

Chief Financial Officer
Strong senior financial executive
with extensive life sciences sector

Debra Wilson

Chief Human Resources
Seasoned leader with more than
25 years’ experience in human
resources, developing and practicing
leading edge methods

Darryl Vleeming

Chief Information Officer
Over 20 years of experience in Senior
IT leadership, project delivery, and IT
strategic planning at publicly traded
international corporations.

Jillian Swainson

Chief Legal Officer
Former Partner at Brownlee LLP with
experience in corporate, commercial,
intellectual property and securities
law and providing advisory services in
highly regulated industries

Neil Belot

Chief Global Business
Development Officer
Former executive director of
Cannabis Canada – Canada’s trade
association for Licensed Producers

Darren Karasiuk

Chief Commercial Officer
Successfully launched Aurora into the
Canadian consumer market, achieving
strong brand recognition for Aurora’s
brands. Former VP Insights & Advisory
at Deloitte

Carey Squires

EVP, Corporate Development
& Strategy
Former Managing Director and CoHead of Equity-Linked Capital Markets
for BMO Capital Markets, with deep
experience in the U.S. and Canadian
capital markets

Company description

About Aurora Cannabis Inc

Aurora Cannabis Inc., through its subsidiaries, is engaged in the production and distribution of medical cannabis. The Company is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering, and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, and home cultivation.


Aurora is one of the largest and fastest growing cannabis companies in the world with a funded production capacity of over 500,000 kilograms per year. Since establishing the Company’s very first facility in Mountain View County, Alberta, Aurora has demonstrated an unprecedented commitment to execution and growth. Today, Aurora has developed an expanding constellation of subsidiaries and strategic partnerships that provide differentiation through its broad global reach, high-yield production techniques, use of advanced technologies and innovative product offering.

With the increasing adoption of medical and adult-consumer use cannabis legalization globally, Aurora has embarked on an aggressive international expansion strategy which currently sees the Company with sales and operations in 24 countries around the world.


Aurora has outpaced its closest industry peers in terms of total registered patients and revenue, despite receiving its sales license 18 months later than the initial licensed group. While the cannabis industry remains in its early stages, by capitalizing rapidly on multiple opportunities, Aurora has quickly become one of the globally dominant companies in the sector.


As the cannabis industry continues to evolve, Aurora continues to implement advanced technologies, create unique products, and research new concepts. This commitment includes the Company’s state-of-the-art “Sky Class” facilities which leverage some of the world’s most technologically advanced cultivation technologies and clone transporters.


Having one of the industry’s strongest balance sheets, Aurora has made a number of strategic investments that are well-integrated with the operational infrastructure of the Company. The value of these investments, which include both public and private companies, have increased significantly providing additional leverage for Aurora to continue to execute on further, accelerated growth opportunities.

  • Upcoming events and next potential milestones
  • Global activities

Investor events and next events:

MJBizCon Europe,Copenhagen, Denmark,May 7 – 10, 2019

The MoneyShow Investment Conference,Las Vegas, USA, May 13 – 15, 2019

Equity Forum German Spring Conference Frankfurt, Germany May 14 – 15, 2019

Canaccord Genuity Cannabis Conference New York City, USA May 14, 2019

BMO 14th Annual Farm to Market Conference New York City, USA May 16, 2019

Cowen Toronto Cannabis Summit Toronto, Canada May 22, 2019

Cannabis World Congress & Business Expo New York City, USA May 29 – 30, 2019

Jefferies 2019 Healthcare Conference New York City, USA June 4 – 5, 2019

Piper Jaffray 39th Annual Consumer Marketplace Conference New York City, USA June 6, 2019

  • Sector leader in technologyacross operationsand product development
  • Active in 5continents and 24 countries
  • Medical cannabis industry leader in Europeand Latin America
  • 14 global production facilities with 3 EU GMP certified
  • 15 strategic acquisitions across the value chain since August 2016
  • 40 Clinical Studies underway or completed (3)and over 73,000 medical patients served